Literature DB >> 9681863

Clinical management of the multiple endocrine neoplasia syndromes: results of a computerized opinion poll at the Sixth International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau disease.

C J Lips1.   

Abstract

OBJECTIVES AND
DESIGN: In order to provide all participants of the Sixth International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau Disease with the opportunity to express their opinion on medical, ethical and social issues on clinical management of these hereditary cancer syndromes, a meeting employing an interactive voting system was organized.
RESULTS: In many aspects, the majority of the participants shared the same opinion. The following percentages of participants felt that, if a specific germline mutation is present in a definitely affected family member, DNA diagnosis should be performed in the offspring of this patient before the age of 10: 78% for MEN-1, 93% for MEN-2, and 71% for VHL. About 71% felt the clinical specialist should provide information about the consequences of DNA analysis and be responsible for disclosing the DNA test results and performing genetic counselling. If possible, selective surgery is preferred to maintain organ function. To make a complete diagnosis in a patient with an apparently sporadic tumour, 89% believed that mutation analysis of germline DNA is mandatory in order to investigate the possibility of inherited disease. In several areas, controversial opinions exist, depending on diversity in discipline, specific research area, experience in the field, and cultural and religious backgrounds. In particular, in vitro fertilization combined with pre-implantation genetic diagnosis is an area which attracts considerable emotion.
CONCLUSIONS: In order to avoid confusion in the families, explicit and common guidelines are needed for the identification, treatment and follow-up of individuals who have predisposing MEN or VHL mutations. Close collaboration between endocrinologists, oncologists, surgeons, pathologists, psychologists and geneticists is required in order to establish and verify such guidelines.

Entities:  

Mesh:

Year:  1998        PMID: 9681863     DOI: 10.1046/j.1365-2796.1998.00375.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  8 in total

1.  Ret proto-oncogene mutations in apparently sporadic Turkish medullary thyroid carcinoma patients: Turkmen study.

Authors:  M F Erdogan; A Gürsoy; G Ozgen; M Cakir; F Bayram; R Ersoy; E Algün; B Cetinarslan; A Cömlekçi; P Kadioglu; M K Balci; I Yetkin; T Kabalak; G Erdogan
Journal:  J Endocrinol Invest       Date:  2005-10       Impact factor: 4.256

2.  Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias.

Authors:  Francesco Tonelli; Geri Fratini; Gabriella Nesi; Maria Silvia Tommasi; Giacomo Batignani; Alberto Falchetti; Maria Luisa Brandi
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

3.  Thyroid cancer: current molecular perspectives.

Authors:  Francesca Giusti; Alberto Falchetti; Francesco Franceschelli; Francesca Marini; Annalisa Tanini; Maria Luisa Brandi
Journal:  J Oncol       Date:  2010-03-29       Impact factor: 4.375

Review 4.  Biliary tree gastrinomas in multiple endocrine neoplasia type 1 syndrome.

Authors:  Francesco Tonelli; Francesco Giudici; Gabriella Nesi; Giacomo Batignani; Maria Luisa Brandi
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

Review 5.  RET and neuroendocrine tumors.

Authors:  Yoshiki Murakumo; Mayumi Jijiwa; Naoya Asai; Masatoshi Ichihara; Masahide Takahashi
Journal:  Pituitary       Date:  2006       Impact factor: 3.599

6.  Gastrinoma in multiple endocrine neoplasia type 1 after total pancreatectomy: A case report.

Authors:  Shu Gong; Zhi Li; Xu-Bao Liu; Xin Wang; Wen-Wu Shen
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

7.  Clinical features and signaling effects of RET D631Y variant multiple endocrine neoplasia type 2 (MEN2).

Authors:  Ji-Young Lee; Su Yeon Kim; Kwan Hoon Jo; Eun Yeong Mo; Eun Sook Kim; Hye Soo Kim; Je Ho Han; Sung-Dae Moon
Journal:  Korean J Intern Med       Date:  2021-12-15       Impact factor: 3.165

8.  Uptake of genetic testing and long-term tumor surveillance in von Hippel-Lindau disease.

Authors:  Astrid Rasmussen; Elisa Alonso; Adriana Ochoa; Irene De Biase; Itziar Familiar; Petra Yescas; Ana-Luisa Sosa; Yaneth Rodríguez; Mireya Chávez; Marisol López-López; Sanjay I Bidichandani
Journal:  BMC Med Genet       Date:  2010-01-12       Impact factor: 2.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.